Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

dermatomyositis skin disease

Roivant Sciences Ltd (NASDAQ:ROIV) and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).

Dermatomyositis is a chronic autoimmune disorder causing muscle inflammation and a distinctive skin rash, often purple or reddish, on areas like the face, knuckles, and upper chest.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.